Certificate of Analysis

Report GSA-COA-000078-TZP40-20261101-7
Issued 2026-11-04 · Page 1 of 2

Scan to verify

Tirzepatide 40 mg

Order GSA-2026-000078 · 6A Labs · 3 vials of one product

Customer	6A Labs
Order	GSA-2026-000078
Label	Tirzepatide 40 mg
Vials tested	3 (D2, E2, F2)
Prepared	29 Oct 2026
Tested	01 Nov 2026, 02 Nov 2026
Tests	Identity, Purity, Content, Impurities, Conformity

IDENTITY

Tirzepatide


confirmed in all 3 vials

PURITY


99.8 %

mean of 3 vials (99.5-100.0 %)

HPLC chromatograms (UV, 214 nm), every vial



Mass spectrum of the main peak, vial D2 (9.70 min)



Results by vial

Vial	Identity	Purity (214 nm)
Vial D2	Confirmed	100.00 %
Vial E2	Confirmed	99.93 %
Vial F2	Confirmed	99.52 %
Average		**99.81 %**
Difference		**0.48 points**

Difference = largest minus smallest vial. Purity is a share of the UV peak area.

APPROVED FOR RELEASE

Ian Ebert, Laboratory Director

Signed electronically
5 Nov 2026, 04:46 UTC
Release record: last page

Results are not covered by ISO/IEC 17025 accreditation.
Results relate only to the sample as received and tested.

Results

Identity	**Identified as tirzepatide in every vial.** Measured mass 4813.1, 4813.1, 4813.3 (average 4813.1; expected 4813.5); retention time matching the tirzepatide reference standard (9.67 min). No semaglutide or retatrutide peak was found.
Purity	**99.81 %** (mean of 3 vials; 99.52-100.00 %) by HPLC with UV detection at 214 nm.
Conformity between vials	**Not consistent.** Content of every vial within +/- 5 % of the three-vial mean: not met, largest difference 17.3 % (RSD 15.1 %). The same peptide is the main compound of every vial (tirzepatide); Purity of every vial within +/- 0.5 percentage points of the mean; Same impurity profile: no impurity of 0.3 % or more in one vial only: met. Criteria are the laboratory's batch-consistency limits for 3 vials; a formal content-uniformity test (USP <905>) needs 10 units.

Impurities

Every peak other than tirzepatide found in the vials, as a share of the UV peak area at 214 nm:

Peak (min)	Vial D2	Vial E2	Vial F2	Mean	What it is
5.89	-	-	0.18 %	0.06 %	An unidentified substance that is not a form of tirzepatide (its mass does not match).
7.39	< 0.01 %	< 0.01 %	0.11 %	0.04 %	A small unidentified peak (too small for its mass to be measured).
8.83	-	-	0.10 %	0.03 %	A closely related form of tirzepatide; its exact structure is unknown.


Trace peaks below 0.10 % add up to 0.00 % (vial D2), 0.07 % (vial E2), 0.09 % (vial F2). '-' = not found in that vial.

Net content

Vial	Net content	% of label
Vial D2	13.7 mg	34.3 %
Vial E2	13.2 mg	33.0 %
Vial F2	17.3 mg	43.2 %
Average	14.7 mg	36.9 %
Difference	4.09 mg (RSD 15.1 %)	10.2 points

Content is the mean of every injection of the vial's solution. Difference = largest minus smallest vial.

Zoomed views



Chain of custody

Receipt photograph of the vials: 29 Oct 2026 12:08, purple cap (6A-TZ 40 mg). Sample preparation was video-recorded on 29 Oct 2026 (4 recordings, each identified by its SHA-256 fingerprint): 1 6a tz 40mg.mp4 (59 s, 4be8c77b43362f02fa5d089a2e4aecdb689d8ded8e9f877919ce0576030c59b6); 2, 6a-tz 40mg.mp4 (51 s, 0b230df5082302a0f1c23c3ad38112e381a3d856e5eae97c4b4af4c6075c2fd7); 3, 6a-tz 40mg.mp4 (42 s, cc6a5f16a96e4928729796e41d552fd0b94e3de5a37efccc5ab87627272e585f); 40mg 6a-tz pt2.mp4 (121 s, 230e9489368f1e91b113e284f30df09349af534f0041d71131ff061c3fef8d38).

How it was tested

Liquid chromatography with UV and mass-spectrometry detection: Agilent 1290 Infinity II LC with a 6490 triple-quadrupole mass spectrometer. Column Polaris C18-A, 2.0 x 150 mm, 55 °C; water and acetonitrile, each with 0.1 % formic acid. Purity: UV peak area at 214 nm. Identity: molecular mass and retention time against a reference standard. Content: UV at 220 nm against a tirzepatide reference standard; the whole vial was dissolved. Each vial was made up to 1 mg/mL from its label claim in 20 % acetonitrile / 80 % water with 0.1 % formic acid.

Notes

Results apply only to the vials as received and tested. Purity is a share of the UV peak area, not a weight percentage. Identity is by molecular mass and retention time; the amino-acid sequence was not checked.

APPROVED FOR RELEASE

Signed electronically by a Gold Standard Analytics lab technician at release.
The signature is at the bottom of page 1; the release record, the last page of this certificate, gives the date and verification code.

Gold Standard Analytics

goldstandardanalytics.com

Release record

Report GSA-COA-000078-TZP40-20261101-7 · Certificate GSA-2026-663293

Customer and order	6A Labs · GSA-2026-000078
Sample and report	078-TZP40 · Tirzepatide 40 mg Certificate of Analysis
Report reference	GSA-COA-000078-TZP40-20261101-7
Certificate accession	GSA-2026-663293
Released and signed by	Ian Ebert, Laboratory Director
Date and time (UTC)	2026-11-05 04:46:17Z
Signature meaning	Approved for release. The signer reviewed this report and approved its release to its customer.
Approval reference	4686f198-3176-4032-ba57-ff19f4f59d33
Electronic signature	Signed electronically in a signed-in GSA staff account.
Original report SHA-256	9e53e5190ab3fd69ce04145cf7587ae87891384cfb0f0b1475e12f4d42238e8f
Verify this certificate	https://goldstandardanalytics.com/coa/GSA-2026-663293

Scan to view this certificate online

Signature



Ian Ebert, Laboratory Director